Versant-backed Firefly Bio wants to make the next generation of ADCs
BioPharma
Source: biopharmadive.com
📰 Versant Ventures News
Page 2 - Versant Ventures News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Versant Ventures. Real-time updates on events, politics, business and more.
Firefly Bio Unveils $94M to Illuminate the Startup's New Take on ADC Cancer Meds
Versant Ventures-backed Firefly Bio is part of a growing group of companies developing degrader antibody conjugates, or DACs. These targeted cancer therapies combine properties of antibody drug conjugates and protein degraders in order to overcome limitations of both types of therapies.
Source: medcitynews.com
Firefly Bio Debuts With $94 Million Series A Financing
-- Transformational degrader antibody conjugate company backed by leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company --SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led b...
Source: pharmiweb.com
Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.
Rob Woodman Enterprise Therapeutics Ltd Novartis Venture Fund Ip Group Versant Ventures Epidarex Capital
Source: news-medical.net
Augmedics CEO takes over corner office at CVRx
CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Hykes as its new president and CEO, effective Feb. 12.
Source: massdevice.com
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets....
Source: prnewswire.com
AbbVie-Backed Disco Launches with $20M in Funding, Targets Oncology
Disco Pharmaceuticals is taking to the biotech dance floor with seed funding from major players and pipeline programs in small cell lung cancer and colorectal cancer.
Johannes Heuckmann Dieter Weinand Roman Thomas Bernd Wollscheid University Of Cologne Disco Pharmaceuticals
Source: biospace.com